|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bratt O: What should a urologist know
about hereditary predisposition to prostate cancer? BJU Int.
99:743–748. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stegeman S, Amankwah E, Klein K, O'Mara
TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles
R, et al: A large-scale analysis of genetic variants within
putative miRNA binding sites in prostate cancer. Cancer Discov.
5:368–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu
H, Liu P, Hao X, Zhang W and Chen K: Functional SNP in the
microRNA-367 binding site in the 3′UTR of the calcium channel
ryanodine receptor gene 3 (RYR3) affects breast cancer risk and
calcification. Proc Natl Acad Sci USA. 108:13653–13658. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minguzzi S, Selcuklu SD, Spillane C and
Parle-McDermott A: An NTD-associated polymorphism in the 3′UTR of
MTHFD1L can affect disease risk by altering miRNA binding. Hum
Mutat. 35:96–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nicoloso MS, Sun H, Spizzo R, Kim H,
Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L,
et al: Single-nucleotide polymorphisms inside microRNA target sites
influence tumor susceptibility. Cancer Res. 70:2789–2798. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chandradoss SD, Schirle NT, Szczepaniak M,
MacRae IJ and Joo C: Dynamic search process underlies MicroRNA
targeting. Cell. 162:96–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Zhang S, Yao J, Lowery FJ, Zhang
Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al:
Microenvironment-induced PTEN loss by exosomal microRNA primes
brain metastasis outgrowth. Nature. 527:100–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuosmanen SM, Viitala S, Laitinen T,
Peräkylä M, Pölönen P, Kansanen E, Leinonen H, Raju S,
Wienecke-Baldacchino A, Närvänen A, et al: The effects of sequence
variation on genome-wide NRF2 binding-new target genes and
regulatory SNPs. Nucleic Acids Res. 44:1760–1775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niu T, Liu N, Zhao M, Xie G, Zhang L, Li
J, Pei YF, Shen H, Fu X, He H, et al: Identification of a novel
FGFRL1 MicroRNA target site polymorphism for bone mineral density
in meta-analyses of genome-wide association studies. Hum Mol Genet.
24:4710–4727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ullrich A, Gray A, Tam AW, Yang-Feng T,
Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et
al: Insulin-like growth factor I receptor primary structure:
Comparison with insulin receptor suggests structural determinants
that define functional specificity. EMBO J. 5:2503–2512. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ofer P, Heidegger I, Eder IE, Schöpf B,
Neuwirt H, Geley S, Klocker H and Massoner P: Both IGF1R and INSR
knockdown exert antitumorigenic effects in prostate cancer in vitro
and in vivo. Mol Endocrinol. 29:1694–1707. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Huang Y, Christie A, Bowden M, Lee
GS, Kantoff PW and Sweeney CJ: Cabozantinib inhibits abiraterone's
upregulation of IGFIR phosphorylation and enhances its
anti-prostate cancer activity. Clin Cancer Res. 21:5578–5587. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Madan RA and Dahut WL: Prostate cancer:
Charting a course in metastatic castration-sensitive prostate
cancer. Nat Rev Urol. 12:368–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Xin X, Li J, Xu J, Yu X, Li T, Mo
Z and Hu Y: RTK/ERK pathway under natural selection associated with
prostate cancer. PLoS One. 8:e782542013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015.doi: 10.7554/eLife.05005. View Article : Google Scholar
|
|
20
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathews DH, Disney MD, Childs JL,
Schroeder SJ, Zuker M and Turner DH: Incorporating chemical
modification constraints into a dynamic programming algorithm for
prediction of RNA secondary structure. Proc Natl Acad Sci USA.
101:7287–7292. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turner DH and Mathews DH: NN DB The
nearest neighbor parameter database for predicting stability of
nucleic acid secondary structure. Nucleic Acids Res. 38:D280–D282.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kertesz M, Iovino N, Unnerstall U, Gaul U
and Segal E: The role of site accessibility in microRNA target
recognition. Nat Genet. 39:1278–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barrett T, Troup DB, Wilhite SE, Ledoux P,
Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M,
Marshall KA, et al: NCBI GEO: Archive for high-throughput
functional genomic data. Nucleic Acids Res. 37:D885–D890. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin HH, Liao CJ, Lee YC, Hu KH, Meng HW
and Chu ST: Lipocalin-2-induced cytokine production enhances
endometrial carcinoma cell survival and migration. Int J Biol Sci.
7:74–86. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin PC, Chiu YL, Banerjee S, Park K,
Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB,
Beltran H, et al: Epigenetic repression of miR-31 disrupts androgen
receptor homeostasis and contributes to prostate cancer
progression. Cancer Res. 73:1232–1244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe
TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al:
Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res. 68:6162–6170.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wach S, Nolte E, Szczyrba J, Stöhr R,
Hartmann A, Ørntoft T, Dyrskjøt L, Eltze E, Wieland W, Keck B, et
al: MicroRNA profiles of prostate carcinoma detected by
multiplatform microRNA screening. Int J Cancer. 130:611–621. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ivey KN, Muth A, Arnold J, King FW, Yeh
RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, et
al: MicroRNA regulation of cell lineages in mouse and human
embryonic stem cells. Cell Stem Cell. 2:219–229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
32
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et
al: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gong Y, Ren J, Liu K and Tang LM: Tumor
suppressor role of miR-133a in gastric cancer by repressing IGF1R.
World J Gastroenterol. 21:2949–2958. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo J, Xia B, Meng F and Lou G: miR-133a
suppresses ovarian cancer cell proliferation by directly targeting
insulin-like growth factor 1 receptor. Tumour Biol. 35:1557–1564.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang W, Liu K, Liu S, Ji B, Wang Y and
Liu Y: MicroRNA-133a functions as a tumor suppressor by targeting
IGF-1R in hepatocellular carcinoma. Tumour Biol. 36:9779–9788.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mitchelson KR and Qin WY: Roles of the
canonical myomiRs miR-1, −133 and −206 in cell development and
disease. World J Biol Chem. 6:162–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rao PK, Kumar RM, Farkhondeh M,
Baskerville S and Lodish HF: Myogenic factors that regulate
expression of muscle-specific microRNAs. Proc Natl Acad Sci USA.
103:8721–8726. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu L, Shao X, Gao W, Zhang Z, Liu P, Wang
R, Huang P, Yin Y and Shu Y: MicroRNA-133b inhibits the growth of
non-small-cell lung cancer by targeting the epidermal growth factor
receptor. FEBS J. 279:3800–3812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duan FT, Qian F, Fang K, Lin KY, Wang WT
and Chen YQ: miR-133b, a muscle-specific microRNA, is a novel
prognostic marker that participates in the progression of human
colorectal cancer via regulation of CXCR4 expression. Mol Cancer.
12:1642013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karatas OF, Guzel E, Suer I, Ekici ID,
Caskurlu T, Creighton CJ, Ittmann M and Ozen M: miR-1 and miR-133b
are differentially expressed in patients with recurrent prostate
cancer. PLoS One. 9:e986752014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lv LV, Zhou J, Lin C, Hu G, Yi LU, DU J,
Gao K and Li X: DNA methylation is involved in the aberrant
expression of miR-133b in colorectal cancer cells. Oncol Lett.
10:907–912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion,
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hu J, Xu Y and Cai S: Specific microRNAs
as novel biomarkers for combination chemotherapy resistance
detection of colon adenocarcinoma. Eur J Med Res. 20:952015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pantaleo MA, Ravegnini G, Astolfi A,
Simeon V, Nannini M, Saponara M, Urbini M, Gatto L, Indio V,
Sammarini G, et al: Integrating miRNA and gene expression profiling
analysis revealed regulatory networks in gastrointestinal stromal
tumors. Epigenomics. 8:1347–1366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dufour A, Sampson NS, Zucker S and Cao J:
Role of the hemopexin domain of matrix metalloproteinases in cell
migration. J Cell Physiol. 217:643–651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kuniyasu H, Ukai R, Johnston D, Troncoso
P, Fidler IJ and Pettaway CA: The relative mRNA expression levels
of matrix metalloproteinase to E-cadherin in prostate biopsy
specimens distinguishes organ-confined from advanced prostate
cancer at radical prostatectomy. Clin Cancer Res. 9:2185–2194.
2003.PubMed/NCBI
|
|
48
|
Kim SA, Inamura K, Yamauchi M, Nishihara
R, Mima K, Sukawa Y, Li T, Yasunari M, Morikawa T, Fitzgerald KC,
et al: Loss of CDH1 (E-cadherin) expression is associated with
infiltrative tumour growth and lymph node metastasis. Br J Cancer.
114:199–206. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bonilla C, Mason T, Long L, Ahaghotu C,
Chen W, Zhao A, Coulibaly A, Bennett F, Aiken W, Tullock T, et al:
E-cadherin polymorphisms and haplotypes influence risk for prostate
cancer. Prostate. 66:546–556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Raffo AJ, Perlman H, Chen MW, Day ML,
Streitman JS and Buttyan R: Overexpression of bcl-2 protects
prostate cancer cells from apoptosis in vitro and confers
resistance to androgen depletion in vivo. Cancer Res.
55:44338–4445. 1995.
|
|
53
|
Huang WC, Chan SH, Jang TH, Chang JW, Ko
YC, Yen TC, Chiang SL, Chiang WF, Shieh TY, Liao CT, et al:
miRNA-491-5p and GIT1 serve as modulators and biomarkers for oral
squamous cell carcinoma invasion and metastasis. Cancer Res.
74:751–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang J, Wang Y, Sun D, Bu J, Ren F, Liu B,
Zhang S, Xu Z, Pang S and Xu S: miR-455-5p promotes cell growth and
invasion by targeting SOCO3 in non-small cell lung cancer.
Oncotarget. 8:114956–114965. 2017.PubMed/NCBI
|
